Quantitative Structure-Retention Relationships for Rapid Method Development in Reversed-Phase Liquid Chromatography

Total Page:16

File Type:pdf, Size:1020Kb

Quantitative Structure-Retention Relationships for Rapid Method Development in Reversed-Phase Liquid Chromatography Quantitative Structure-Retention Relationships for Rapid Method Development in Reversed-Phase Liquid Chromatography Yabin Wen M.Sc. Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy School of Physical Sciences University of Tasmania June 2018 i Declaration This thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain any material that infringes copyright. This thesis may be made available for loan and limited copying and communication in accordance with the Copyright Act 1968. The publishers of the papers in this thesis hold the copyright for that content, and access to the material should be sought from the respective journals. The remaining non published content of the thesis may be made available for loan and limited copying and communication in accordance with the Copyright Act 1968. Yabin Wen May 2018 ii Statement of co-authorship The following people and institutions contributed to the publication of work undertaken as part of this thesis: Candidate: Yabin Wen, ACROSS, School of Physical Sciences, UTAS Paul R. Haddad, ACROSS, School of Physical Sciences, UTAS Ruth I.J. Amos, ACROSS, School of Physical Sciences, UTAS Mohammad Talebi, ACROSS, School of Physical Sciences, UTAS Robert Shellie, ACROSS, School of Physical Sciences, UTAS Eva Tyteca, ACROSS, School of Physical Sciences, UTAS Maryam Taraji, ACROSS, School of Physical Sciences, UTAS Soo Hyun Park, ACROSS, School of Physical Sciences, UTAS Roman Szucs, Pfizer Global Research and Development, Sandwich, United Kingdom John W. Dolan, LC Resources, McMinnville, Oregon, United States Chris A. Pohl, Thermo Fisher Scientific, Sunnyvale, California, United States Author details and their roles: Paper 1, “Towards a chromatographic similarity index to establish localised quantitative structure-retention models for retention prediction: use of retention factor ratio”, located in Chapter 3. E. Tyteca (50%), M. Talebi (7%), R.I.J. Amos (7%), Y. Wen (Candidate, 5%), S.H. Park (5%), M. Taraji (5%), R. Szucs (2%), C.A. Pohl (2%), J.W. Dolan (2%), P.R. Haddad (15%). • E. Tyteca was the primary author with P.R. Haddad, M. Talebi, and R.I.J. Amos contributed to the idea, its formulation and development. • P.R. Haddad, M. Talebi and R.I.J. Amos assisted with refinement and presentation. • Y. Wen (Candidate), S.H. Park, and M. Taraji offered retention data and molecular descriptors for the modelling, along with preliminary results for the pilot study, and offered some descriptions in the experimental section of the manuscript. • R. Szucs, C.A. Pohl and J.W. Dolan established the need of study and provided feedback on the work. iii Paper 2, “Retention time prediction based on molecular structure in pharmaceutical method development: A perspective”. M. Talebi (50%), Robert A. Shellie (7%), R.I.J. Amos (7%), Y. Wen (Candidate, 5%), S.H. Park (5%), M. Taraji (5%), R. Szucs (2%), C.A. Pohl (2%), J.W. Dolan (2%), P.R. Haddad (15%). • M. Talebi was the primary author with P.R. Haddad, Robert A. Shellie, and R.I.J. Amos contributed to the idea, its formulation and development. • P.R. Haddad, Robert A. Shellie and R.I.J. Amos assisted with refinement and presentation. • Y. Wen (Candidate), S.H. Park, and M. Taraji offered retention data and molecular descriptors for the modelling, along with preliminary results for the pilot study, and offered some descriptions in the experimental section of the manuscript. • R. Szucs, C.A. Pohl and J.W. Dolan established the need of study and provided feedback on the work. Paper 3, “Retention prediction in reversed phase high performance liquid chromatography using quantitative structure-retention relationships applied to the Hydrophobic Subtraction Model”, located in Chapter 4. Y. Wen (Candidate, 50%), M. Talebi (15%), R.I.J. Amos (15%), R. Szucs (2%), C.A. Pohl (1%), J.W. Dolan (2%), P.R. Haddad (15%). • Y. Wen was the primary author with P.R. Haddad, M. Talebi, and R.I.J. Amos contributed to the idea, its formulation and development. • P.R. Haddad, M. Talebi and R.I.J. Amos assisted with refinement and presentation. • M. Talebi provided general laboratory assistance and GA-PLS algorithm for the modelling. • R. Szucs, C.A. Pohl and J.W. Dolan established the need of study and provided feedback on the work. Paper 4, “Retention index prediction using quantitative structure-retention relationships for improving structure identification in Non-Targeted Metabolomics”, under revision after favourable review, located in Chapter 5. Y. Wen (Candidate, 50%), R.I.J. Amos (15%), M. Talebi (15%), R. Szucs (2%), C.A. Pohl (1%), J.W. Dolan (2%), P.R. Haddad (15%). • Y. Wen was the primary author with P.R. Haddad, M. Talebi, and R.I.J. Amos contributed to the idea, its formulation and development. iv • P.R. Haddad, M. Talebi and R.I.J. Amos assisted with refinement and presentation. • M. Talebi provided general laboratory assistance and GA-PLS algorithm for the modelling. • R. Szucs, C.A. Pohl and J.W. Dolan established the need of study and provided feedback on the work. Signed: Signed: Signed: Paul R. Haddad Ruth I.J. Amos Jason Smith Supervisor Co-Supervisor Head, Discipline of School of Natural School of Natural Chemistry Sciences Sciences School of Natural University of Tasmania University of Tasmania Sciences University of Tasmania v List of publications and presentations Publications: 1. Y. Wen, R.I.J. Amos, M. Talebi, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Retention index prediction using quantitative structure-retention relationships for improving structure identification in Non-Targeted Metabolomics”, Anal. Chem. 90.15 (2018): 9434-9440. (Chapter 5) 2. Y. Wen, M. Talebi, R.I.J. Amos, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Retention prediction in reversed phase high performance liquid chromatography using quantitative structure-retention relationships applied to the Hydrophobic Subtraction Model”, J. Chromatogr. A 1541 (2018): 1-11. (Chapter 4) 3. E. Tyteca, M. Talebi, R.I.J. Amos, S.H. Park, M. Taraji, Y. Wen, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Towards a chromatographic similarity index to establish localised quantitative structure-retention models for retention prediction: use of retention factor ratio”, J. Chromatogr. A 1486 (2017) 50-58. (Chapter 3) 4. M. Talebi, S.H. Park, M. Taraji, Y. Wen, R.I.J. Amos, P.R. Haddad, R.A. Shellie, R. Szucs, C.A. Pohl, J.W. Dolan. “Retention time prediction based on molecular structure in pharmaceutical method development: a perspective”, LCGC North America 34 (8) (2016): 550-558. Presentations: 5. P.R. Haddad, Y. Wen, R.I.J. Amos, M. Talebi, R. Szucs, C.A. Pohl, J.W. Dolan. “Quantitative structure-retention relationships for retention prediction in RPLC and their application to early stage drug development and non-targeted metabolomics”, ISCC 2018, Riva del Garda, Italy. (Oral) 6. Y. Wen, R.I.J. Amos, M. Talebi, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Retention prediction in reversed-phase high performance liquid chromatography using quantitative structure-retention relationships applied to the Hydrophobic Subtraction Model”, RACI R&D Topics 2017, Hobart, Australia. (Oral) 7. Y. Wen, R.I.J. Amos, M. Talebi, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Retention prediction in reversed phase HPLC using Quantitative Structure-Retention Relationships applied to the Hydrophobic Subtraction Model”, HPLC 2017, Prague, Czech Republic. (Oral) 8. Y. Wen, P.R. Haddad, R.I.J. Amos, M. Talebi, R. Szucs, C.A. Pohl, J.W. Dolan, R.A. Shellie. “Similarity Searching in Quantitative Structure-Retention Relationship for Retention vi Prediction in Reversed-Phase Liquid Chromatography”, ASASS2 2016, Hobart, Australia. (Oral) 9. P.R. Haddad, S.H. Park, M. Taraji, Y. Wen, E. Tyteca, M. Talebi, R.I.J. Amos, R.A. Shellie, R. Szucs, C.A. Pohl, J.W. Dolan. “Prediction of chromatographic retention times based on chemical structures of analytes”, ASASS2 2016, Hobart, Australia. (Oral) 10. P.R. Haddad, S.H. Park, M. Taraji, Y. Wen, M. Talebi, R.I.J. Amos, R.A. Shellie, R. Szucs, C.A. Pohl, J.W. Dolan. “Role of Structural Similarity in Prediction of Retention in Reversed- Phase, Ion-Exchange and Hydrophilic Interaction Liquid Chromatography Modes Using Quantitative Structure-Retention Relationships”, HPLC 2016, San Francisco, USA. (Oral) 11. P.R. Haddad, S.H. Park, M. Taraji, Y. Wen, E. Tyteca, M. Talebi, R.I.J. Amos, R.A. Shellie, R. Szucs, C.A. Pohl, J.W. Dolan. “Prediction of retention times in reversed-phase, ion- exchange and HILIC modes based on chemical structures”, ISC 2016, Cork, Ireland. (Oral) 12. Y. Wen, M. Talebi, R.I.J. Amos, R.A. Shellie, R. Szucs, C.A. Pohl, J.W. Dolan, P.R. Haddad. “Prediction of retention times in reversed-phase liquid chromatography based on chemical structures of analytes”, RACI R&D Topics 2015, Melbourne, Australia. (Poster) vii Acknowledgements First of all, I would like to offer this thesis to my unborn child, the biggest surprise in my life. I predicted my 33rd year would be a powerful one, now you are the answer. Hope that one day you will be proud of your father. Especially, I would like to sincerely thank my primary supervisor, Prof. Paul Haddad, for his guidance and support throughout my study and my life. Being his last PhD student is an honour, and I will never forget his professionalism, humility, and kindness.
Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • MDPV Bath Salts Test
    One Step Methylenedioxypyrovalerone Drug of Abuse Test MATERIALS Analytical Sensitivity The cut-off concentration of the One Step Methylenedioxypyrovalerone Drug of Abuse Test is determined to be 1,000ng/mL. (Dip Card) Materials Provided: Test was run in 30 replicates with negative urine and standard control at ±25% cut-off and ±50% cut-off concentration levels. Test results ● Dip cards are summarized below. For Forensic Use Only ● Desiccants ● Package insert Test Result INTENDED USE Percent of Cut-off n Materials Required But Not Provided: Methylenedioxypyrovalerone Concentration in ng/mL The One Step Methylenedioxypyrovalerone Drug of Abuse Test is a lateral flow chromatographic immunoassay for the ● Specimen collection container Negative Positive qualitative detection of Methylenedioxypyrovalerone (MDPV) in human urine specimen at the cut-off level of 1,000ng/mL. This ● Disposable gloves 0% Cut-off assay is intended for forensic use only. ● Timer 30 30 0 This assay provides only a preliminary qualitative test result. A more specific confirmatory reference method, such as Liquid (No Drug Present) chromatogra -50% Cut-off phy tandem mass spectrometry (LC/MS/MS) or gas chromatography/mass spectrometry (GC/MS) must be use in INSTRUCTIONS FOR USE] 30 30 0 order to obtain a confirmed analytical result. (500ng/mL) 1) Remove the dip card from the foil pouch. -25% Cut-off 30 30 0 BACKGROUND 2) Remove the cap from the dip card. Label the device with patient or control identifications. (750ng/mL) 3) Immerse the absorbent tip into the urine sample for 5 seconds. Urine sample should not touch the plastic device. Cut-off ‘Bath salts’, a form of designer drugs, also promoted as ‘plant food’ or ‘research chemicals’, is sold mainly in head shops, on 4) Replace the cap over the absorbent tip and lay the dip card on a clean, flat, and non-absorptive surface.
    [Show full text]
  • PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
    PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Temporary Class Drug Order Report: 5-6APB and Nbome Compounds
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives.
    [Show full text]
  • The Place of Physical Exercise and Bronchodilator Drugs in the Assessment of the Asthmatic Child
    Arch Dis Child: first published as 10.1136/adc.38.202.539 on 1 December 1963. Downloaded from Arch. Dis. Childh., 1963, 38, 539. THE PLACE OF PHYSICAL EXERCISE AND BRONCHODILATOR DRUGS IN THE ASSESSMENT OF THE ASTHMATIC CHILD BY R. S. JONES, M. J. WHARTON and M. H. BUSTON From Alder Hey Children's Hospital and the Department of Child Health, University ofLiverpool (RECEIVED FOR PUBLICATION MAY 9, 1963) Among the many factors that affect ventilatory exercise. Isoprenaline sulphate I % (Burroughs Wellcome function in the asthmatic subject, physical exercise preparation) was given as an aerosol using a Wright and bronchodilator drugs are two of the more inhaler and an air flow rate of 8-9 litres per minute important. It has been shown that physical exercise (Wright, 1958). The aerosol was fed into a face mask has two distinct and opposite effects on ventilatory held close to the face. The substance was inhaled for one minute and for two subsequent half-minute periods function depending upon the duration and level of during a total time of five minutes. Solutions of exercise (Jones, Buston and Wharton, 1962). adrenaline and noradrenaline were made up from the Providing the level is adequate, exercise lasting less solid substances (Burroughs Wellcome preparations) in than two minutes increases the forced expiratory strengths of 1% with added sodium metabisulphite. volume in one second (F.E.V.), whereas exercise These preparations were used fresh and were inhaled by copyright. lasting eight to 10 minutes produces a fall of F.E.V. in the same way as isoprenaline.
    [Show full text]
  • Regulations 2021
    STATUTORY INSTRUMENTS. S.I. No. 121 of 2021 ________________ MISUSE OF DRUGS (AMENDMENT) REGULATIONS 2021 2 [121] S.I. No. 121 of 2021 MISUSE OF DRUGS (AMENDMENT) REGULATIONS 2021 I, STEPHEN DONNELLY, Minister for Health, in exercise of the powers conferred on me by sections 4, 5 (amended by section 3 of the Misuse of Drugs (Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act 1977 (No. 12 of 1977) and section 5 of the Misuse of Drugs Act 1984 (No. 18 of 1984), hereby make the following regulations: 1. These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations 2021. 2. The Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017) are amended by the substitution of the following Schedule for Schedule 1: Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 23rd March, 2021. [121] 3 “Schedule 1 1. The following substance and products, namely- (a) N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (otherwise known as Clockwork Orange, 5F AKB48) N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide (otherwise known as ADB-CHMINACA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1H-indazole- 3-carboxamide (otherwise known as ADB-FUBINACA) N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide (otherwise known as AB-CHMINACA) N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-pentyl-1H-indazole-3- carboxamide (otherwise known as AB-PINACA) 5-(2-Aminopropyl)indole (otherwise known
    [Show full text]
  • (LSD) Test Dip Card (Urine) • Specimen Collection Container % Agreement 98.8% 99
    frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing. GC/MS. The following results were tabulated: Method GC/MS MATERIALS Total Results Results Positive Negative Materials Provided LSD Rapid Positive 79 1 80 LSD • Test device • Desiccants • Package insert • Urine cups Test Dip card Negative 1 99 100 Materials Required But Not Provided Total Results 80 100 180 One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) • Specimen collection container % Agreement 98.8% 99. % 98.9% • Timer Package Insert DIRECTIONS FOR USE Analytical Sensitivity This Instruction Sheet is for testing of Lysergic acid diethylamide. Allow the test device, and urine specimen to come to room temperature [15-30°C (59-86°F)] prior to testing. A drug-free urine pool was spiked with LSD at the following concentrations: 0 ng/mL, -50%cutoff, -25%cutoff, cutoff, A rapid, one step test for the qualitative detection of Lysergic acid diethylamide and its metabolites in human urine. 1) Remove the test device from the foil pouch. +25%cutoff and +50%cutoff. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off For forensic use only. 2) Remove the cap from the test device. Label the device with patient or control identifications. concentration. The data are summarized below: INTENDED USE 3) Immerse the absorbent tip into the urine sample for 10-15 seconds. Urine sample should not touch the plastic Lysergic acid diethylamide (LSD) Percent of Visual Result The One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) is a lateral flow chromatographic device.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]